Supernus Pharmaceuticals Inc (SUPN) — Capital Reinvestment Ratio

Latest as of December 2025: 0.02x

Supernus Pharmaceuticals Inc (SUPN) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow ($19.86 Million) in capital expenditures ($427.00K). Check SUPN tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.02x
Capex / Operating Cash Flow

Operating Cash Flow

$19.86 Million
USD

Capital Expenditures

$427.00K
USD

Data as of

Dec 2025
Most recent filing

Supernus Pharmaceuticals Inc Capital Reinvestment Ratio (2009–2025)

This chart tracks Supernus Pharmaceuticals Inc's Capital Reinvestment Ratio across 13 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Supernus Pharmaceuticals Inc.

Annual Capital Reinvestment Ratio for Supernus Pharmaceuticals Inc (2009–2025)

Year-by-year Capital Reinvestment Ratio for Supernus Pharmaceuticals Inc from 2009 to 2025. See Supernus Pharmaceuticals Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.03x $47.33 Million $1.34 Million ▲ +570.5%
2024 0.00x $171.95 Million $725.00K ▼ -15.0%
2023 0.00x $111.08 Million $551.00K ▲ +40.6%
2022 0.00x $116.83 Million $412.00K ▼ -78.1%
2021 0.02x $127.13 Million $2.04 Million ▼ -35.5%
2020 0.02x $138.40 Million $3.45 Million ▲ +30.4%
2019 0.02x $143.13 Million $2.74 Million ▲ +192.1%
2018 0.01x $128.99 Million $844.00K ▼ -63.0%
2017 0.02x $114.64 Million $2.03 Million ▼ -26.2%
2016 0.02x $66.81 Million $1.60 Million ▼ -63.4%
2015 0.07x $32.12 Million $2.10 Million ▼ -14.6%
2014 0.08x $7.73 Million $593.00K ▼ -71.7%
2009 0.27x $2.63 Million $714.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow